What is the prognosis for a 9‑centimeter hepatic mass?

Prognosis for a 9cm Hepatic Mass

A 9cm liver mass carries a guarded prognosis with significant variability depending on underlying liver function, tumor characteristics, and treatment approach—if this is hepatocellular carcinoma (HCC) in a cirrhotic patient, expect intermediate-stage disease (BCLC Stage B) with median survival of 16-20 months with transarterial chemoembolization (TACE), though surgical resection in carefully selected patients without cirrhosis or portal hypertension can achieve 5-year survival rates of 50-70%. 1, 2

Critical Prognostic Determinants

The prognosis hinges on several key factors that must be immediately assessed:

Liver Function Status

• Child-Pugh Class A with no portal hypertension: Best candidates for curative resection with 5-year survival potentially reaching 50-70% 1
• Child-Pugh Class B or presence of portal hypertension: Poor resection candidates with significantly worse outcomes; median survival drops to approximately 14 months even with treatment 3
• Child-Pugh Class C: End-stage disease with median survival less than 3 months 4

Tumor Characteristics That Worsen Prognosis

A 9cm mass significantly increases risk of:

• Microvascular invasion: Present in approximately 55-63% of tumors >5cm 5
• Satellite nodules: Incidence increases substantially with tumor size 6
• Poor histologic grade: 54% of lesions 5.1-6.5cm are high grade compared to 36% in smaller tumors 5
• Vascular invasion: Independent predictor of poor survival and recurrence 6, 7

Performance Status

• ECOG 0: Eligible for curative or palliative treatments
• ECOG 1-2: Advanced stage (BCLC C) with median survival of 6-7 months without systemic therapy 2
• ECOG 3-4: Terminal stage with median survival <3 months 4

Treatment-Specific Prognosis

If Resectable (Non-Cirrhotic or Child-Pugh A Without Portal Hypertension)

Surgical resection remains the optimal therapy for large HCC when feasible 8:

• 5-year overall survival: 50-58% for tumors 5-10cm 6, 7
• Median disease-free survival: 8.4 months (high recurrence rate) 7
• 50% develop postoperative complications with very large tumors 7
• Critical caveat: Tumor size >5cm itself is NOT an independent predictor of survival on multivariate analysis—rather, the associated microvascular invasion, satellite nodules, and cirrhosis drive poor outcomes 6

If Unresectable (Cirrhotic, Multifocal, or Poor Liver Function)

TACE is the standard palliative treatment for intermediate-stage disease 1:

• Median survival: 19-20 months with TACE versus 16 months untreated 2
• 3-year survival: Up to 50% in optimal responders 4
• Drug-eluting bead TACE (DEB-TACE) minimizes systemic toxicity 1

Combination locoregional therapy (ablation plus TACE) may be considered for intermediate-size lesions >3-4cm to improve tumoricidal effects 8

Advanced Disease with Vascular Invasion or Metastases

Sorafenib or lenvatinib as first-line systemic therapy 3:

• Median survival: 6-7 months (BCLC Stage C) 2
• Only for Child-Pugh A patients with ECOG 0-2 3

Common Pitfalls to Avoid

1. Do not assume size alone determines resectability: A solitary 9cm tumor in a non-cirrhotic liver without vascular invasion may still be resectable with curative intent 6

2. Do not overlook portal hypertension assessment: Even Child-Pugh A patients with clinically significant portal hypertension (esophageal varices, splenomegaly, platelets <100,000) have substantially worse outcomes after resection 1, 3

3. Do not offer resection to Child-Pugh B/C patients: These patients face unacceptable perioperative mortality and should be considered for transplantation if meeting criteria, or palliative therapy 8

4. Recognize that recurrence is the rule, not the exception: 71% of patients with very large HCC (≥10cm) develop recurrences after resection, with 50% having initial extrahepatic recurrence 9, 7

Staging Framework

Use the BCLC staging system to guide prognosis and treatment 1, 10:

• Stage A (Early): Single 9cm tumor, Child-Pugh A, ECOG 0 → Consider resection (5-year survival 50-70%)
• Stage B (Intermediate): Multinodular or unresectable, Child-Pugh A-B, ECOG 0 → TACE (median survival 16-20 months)
• Stage C (Advanced): Vascular invasion or metastases, ECOG 1-2 → Systemic therapy (median survival 6-7 months)
• Stage D (Terminal): Child-Pugh C or ECOG 3-4 → Best supportive care (median survival <3 months)

Bottom Line on Prognosis

For a 9cm liver mass presumed to be HCC:

• Best case scenario (non-cirrhotic, resectable, no vascular invasion): 5-year survival 50-70% with surgery 1
• Intermediate scenario (cirrhotic Child-Pugh A, unresectable): Median survival 16-20 months with TACE 2
• Poor scenario (vascular invasion, extrahepatic spread, or poor liver function): Median survival 3-7 months 4, 2

The presence of cirrhosis, microvascular invasion, satellite nodules, and impaired liver function are the true determinants of poor prognosis—not the 9cm size itself 6.